Standard BioTools logo
Standard BioTools
LAB | NASDAQ
Chart Builder DCF Calculator
$0.62
-$0.09 (-12.36%)
At close: Nov 16, 2026, 4:00 PM ET
$0.60
-$0.02 (-3.06%)
After-hours: Nov 16, 2026, 7:30 PM ET

Standard BioTools Company Profile

Company profile explained

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Key Executives

Name Position
Michael Egholm President, Chief Executive Officer & Director
Hanjoon Kim Chief Financial Officer
Anders Davas Senior Vice President of Global Operations
Elizabeth R. Jensen Chief Human Resources Officer
John Graziano Vice President of Investor Relations
Jonathan Mickelsen Vice President & Chief Accounting Officer
Mike Musgnug Senior Vice President & Chief Commercial Officer
Sean Mackay Chief Business Officer & Senior Vice President

Latest SEC Filings

Date Type Title
Oct 30, 2026 424B3 Filing
Oct 21, 2026 EFFECT Filing
Oct 21, 2026 424B3 Filing
Oct 21, 2026 S-4/A [Amend] Filing
Oct 09, 2026 S-4/A [Amend] Filing
Oct 05, 2026 425 Filing
Oct 05, 2026 8-K Current Report
Sep 30, 2026 425 Filing
Sep 30, 2026 8-K Current Report
Sep 09, 2026 S-4/A [Amend] Filing
View All SEC Filings ➞
Standard BioTools
Standard BioTools logo
Country United States
IPO Date Feb 10, 2011
Industry Medical - Specialties
Sector Healthcare
Employees 387
CEO Michael Egholm

Contact Details

50 Milk Street Boston, Massachusetts 02109 United States

Stock Details

Ticker Symbol LAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001162194
CUSIP Number 34385P108
ISIN Number US34385P1084
SIC Code 3826

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.